AbbVie Inc. (ABBV)
| Market Cap | 504.37B +26.2% |
| Revenue (ttm) | 64.39B +10.4% |
| Net Income | 6.27B +67.7% |
| EPS | 3.54 +68.5% |
| Shares Out | 1.77B |
| PE Ratio | 80.63 |
| Forward PE | 18.95 |
| Dividend | $6.92 (2.42%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 5,643,863 |
| Open | 283.61 |
| Previous Close | 283.40 |
| Day's Range | 282.96 - 286.64 |
| 52-Week Range | 190.75 - 291.40 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 282.61 (-0.98%) |
| Earnings Date | Oct 30, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $282.61, which is a decrease of -0.98% from the latest price.
News
AbbVie announces new, updated data from solid tumor portfolio at ESMO 2026
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO, Congress, taking place October…
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through nex...
AbbVie presents 20 scientific abstracts from its IBD portfolio
AbbVie (ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology, UEG, Week, October 17-20 in Barcelona, Spain. Key data to…
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and RI...
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
AbbVie announces presentation of 22 scientific abstracts from IBD portfolio
AbbVie (ABBV) announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease, IBD, portfolio at the American College of Gastroenterology, ACG, 2026 Annual Sci...
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed su...
Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look
AbbVie ($ABBV), Johnson & Johnson ($JNJ), and Medtronic ($MDT) are three healthcare companies with established dividend-growth records and deserve a closer look. All three stocks are Dividend Aristocr...
AbbVie price target raised to $275 from $260 at UBS
UBS analyst Michael Yee raised the firm’s price target on AbbVie (ABBV) to $275 from $260 and keeps a Neutral rating on the shares. The firm previewed Q3 earnings for…
AbbVie price target raised to $305 from $289 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $305 from $289 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview for…
AbbVie price target raised to $300 from $285 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on AbbVie (ABBV) to $300 from $285 and keeps an Overweight rating on the shares ahead of the Q3 report. The…
AbbVie price target raised to $290 from $285 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $290 from $285 and keeps an Overweight rating on the shares. Skyrizi and Rinvoq scripts are tracking below consensus,…
AI ETFs: Beyond Chips & Hyperscalers
While AI investing initially centered on hyperscalers and chips, the opportunity has been broadening as infrastructure grows. Opportunities are moving further down and across the supply chain — into m...
3 ‘Strong Buy’ Dividend Aristocrat Stocks on Analysts’ Watch List
Johnson & Johnson ($JNJ), Abbott Laboratories ($ABT), and AbbVie ($ABBV) are three Dividend Aristocrat stocks rated Strong Buy by the top Wall Street analysts covering each company, according to TipRa...
AbbVie price target raised to $310 from $296 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $310 from $296 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations
AbbVie (ABBV) announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan in colorectal cancer and non-small cell lung cancer. Temab-A has received two B...
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal ...
AbbVie price target raised to $320 from $280 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on AbbVie (ABBV) to $320 from $280 and keeps an Outperform rating on the shares. The increased price target is driven…
AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84
The company states: “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a…
AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01
16:31 EDT AbbVie (ABBV) sees FY26 EPS $13.76-$13.96, consensus $14.01
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in...
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody ad...
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS)...
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating ...